Climb Bio, Inc. (CLYM) vs SOPHiA GENETICS S.A. (SOPH)

A side-by-side comparison of Climb Bio, Inc. and SOPHiA GENETICS S.A. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CLYM

Climb Bio, Inc.

$618M

$10.79HealthcareDelayed quote: Oct 6, 2026, 2:45 PM EDT

SOPH

SOPHiA GENETICS S.A.

$626M

$7.46HealthcareDelayed quote: Oct 6, 2026, 2:45 PM EDT

Total return — CLYM vs SOPH

growth of $100 · dividends reinvested · last 2y

CLYM +41.1% (+18.8%/yr)SOPH +122.2% (+49.1%/yr)SOPH compounded faster over this window

CLYM SOPH

CLYM vs SOPH: by the numbers

•SOPH is the larger company ($626M vs $618M market cap).
•Both run net losses; CLYM's is the smaller (0.00% vs -93.86% net margin).

Metrics side by side

Valuation

Metric	CLYM	SOPH
P/S ratio	N/A	7.26
P/B ratio	2.58	7.53

Profitability

Metric	CLYM	SOPH
Gross margin	0.00%	66.63%
Operating margin	0.00%	-85.01%
Net margin	0.00%	-93.86%
ROE	-24.06%	-97.31%
ROIC	-26.94%	-49.73%

Growth (annualized)

Metric	CLYM	SOPH
Revenue CAGR (5Y)	N/A	20.33%
Total return CAGR (5Y)	N/A	-13.62%

Go deeper

Full CLYM analysis Full SOPH analysis Interactive comparison tool

Dig into the metrics

Climb Bio ROE SOPHiA GENETICS ROE Climb Bio operating margin SOPHiA GENETICS operating margin Climb Bio revenue growth SOPHiA GENETICS revenue growth Climb Bio free cash flow SOPHiA GENETICS free cash flow

Climb Bio & SOPHiA GENETICS appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.